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Kinetic Solubility
The aqueous solubility of the test compounds was measured using laser nephelometry. Compounds were subject to serial dilution from 10 mM to 0.5 mM in DMSO. An aliquot was then mixed with MilliQ water to obtain an aqueous dilution plate with a final concentration range of 250 -12 µM, with a final DMSO concentration of 2.5%. Triplicate aliquots were transferred to a flat bottomed polystyrene plate which was immediately read on the NEPHELOstar (BMG Lab Technologies). The amount of laser scatter caused by insoluble particulates (relative nephelometry units, RNU) was plotted against compound concentration using a segmental regression fit, with the point of inflection being quoted as the compounds aqueous solubility (µM).
All values reported correspond to n of 1.
pKa
Sirius T3 (Sirius Analytical Inc, UK) instrument has been used for pK a determination of the compounds. The pK a determination is based on acid-base titration and the protonation/deprotonation of the molecule is measured either by UV spectroscopy or potentiometrically. The pK a value is calculated from the pH where the 50-50% of the protonated and unprotonated form of the molecules are present. The UV-metric method provides pK a results for samples with chromophores whose UV absorbance changes as a function of pH. It typically requires 5 µl of a 10 mM solution of the samples and the UV absorbance is monitored over 54 pH values in a buffered solution in about 5 min. When the ionization centre is far from the UV chromophore pHmetric method based on potentiometric acid-base titration is used. The pH of each point in the titration curve is calculated using equations that contain pK a , and the calculated points are fitted to the measured curve by manipulating the pK a . The pK a that provides the best fit is taken to be the measured pK a . Usually 0.5 -1 mg of solid material is required for the measurements. When the compound precipitates at some point during the pH titration co-solvent method using methanol is applied using various concentration of co-solvent. The pK a in water is calculated using the YasudaShedlovsky extrapolation method.
Human Liver Microsome (HLM) stability experiments
Test compound (0.5 μM) was incubated with female CD1 mouse liver microsomes (Xenotech LLC TM; 0.5 mg/mL 50 mM potassium phosphate buffer, pH 7.4) and the reaction started with addition of excess NADPH (8 mg/mL 50 mM potassium phosphate buffer, pH 7.4). Immediately, at time zero, then at 3, 6, 9, 15 and 30 min an aliquot (50 uL) of the incubation mixture was removed and mixed with acetonitrile (100 μL) to stop the reaction. Internal standard was added to all samples, the samples centrifuged to sediment precipitated protein and the plates then sealed prior to UPLCMSMS analysis using a Quattro Premier XE (Waters Corporation, USA). XLfit (IDBS, UK) was used to calculate the exponential decay and consequently the rate constant (k) from the ratio of peak area of test compound to internal standard at each timepoint. The rate of intrinsic clearance (CLi) of each test compound was then calculated using the following calculation:
CLi (mL/min/g liver) = k x V x Microsomal protein yield Where V (mL/mg protein) is the incubation volume/mg protein added and microsomal protein yield is taken as 52.5 mg protein per g liver. Verapamil (0.5 μM) was used as a positive control to confirm acceptable assay performance. Experiments were performed using a single timecourse experiment.
Human Liver Hepatocyte (HLH) stability experiments
Cryopreserved vials of human cryopreserved hepatocytes, supplied by Life Technologies, were thawed according to manufacturer's instructions and cells resuspended in Williams Medium E (WME) containing cell maintenance supplement pack (CM4000, Life Technologies). Hepatocytes were incubated in suspension (0.5 million cells/mL) in 48 well non-collagen coated cell culture plates for 10 minutes at 37 ˚C, 5% CO 2 . Upon addition of an equal volume of supplemented WME containing 1 μM test compound, an aliquot of incubation solution was removed to acetonitrile containing internal standard (final concentration 0.5 μM test compound and a cell density of 0.25 million cells/mL). Similarly, aliquots were removed at 3, 6, 9, 15, 30, 45, 60, 90 and 120 minutes. 100 μL of 80:20 water:acetonitrile was added to all samples and the analysis plate was centrifuged for 10 min at room temperature prior to injection and analysis of samples by UPLC-MS/MS. The response (area ratio of test compound to internal standard) was plotted against time using an exponential decay model and rate of disappearance calculated.
Human Skin S9 stability experiments
An incubation mix was prepared containing 50 mM potassium phosphate buffer, pH 7.4), 0.3 mg/mL human skin S9 (Sekisui Xenotech), NADPH (final concentration 0.8 mg/mL), UDPGA (final concentration 0.16 mg/mL) and warmed to 37 ˚C for 5 minutes. The reaction was initiated upon addition of test compound (final concentration 0.5 μM). Immediately, at time zero, then at 3, 6, 15, 30, 60, 120 and 180 minutes, an aliquot (50 μL) of the incubation mixture was removed and mixed with acetonitrile (100 μL) to terminate the reaction. Internal standard was added to all samples, the samples centrifuged to sediment precipitated protein and the plates then sealed prior to UPLCMSMS analysis using a Quattro Premier XE (Waters corporation, USA).
Grafit (Erithacus Ltd) was used to calculate the exponential decay and consequently the rate constant (k) from the ratio of peak area of test compound to internal standard at each timepoint. The half life (T ½ ) of each test compound was determined using the following equation:
In vivo pharmacokinetics
All regulated procedures on living animals in the University of Dundee were carried out under the authority of a project licence issued by the Home Office under the Animals (Scientific Procedures) Act 1986, as amended in 2012 (and in compliance with EU Directive EU/2010/63). Licence applications will have been approved by the University's Ethical Review Committee (ERC) before submission to the Home Office. The ERC has a general remit to develop and oversee policy on all aspects of the use of animals on University premises and is a sub-committee of the University Court, its highest governing body.
A 22.5 µL single dose of compound (10a) at a 1% w/v concentration in a propylene glycol:ethanol 7:3 formulation was applied topically to a 1.5 cm 2 area of shaved skin on female Balb/c mice. The skin was shaved 24 h prior to treatment. Two hours post application (n=3 mice) or eight hours post application (n=3 mice) a blood sample was taken from each mouse and diluted with nine volumes of sterile water. The mice were then humanely killed. The exposed skin at the application site on each mouse was cleaned with vehicle to remove excess dose and the skin dissected. The diluted blood samples and skin samples were stored frozen prior to analysis of compound 10a levels by UPLC/MS/MS. 8h-post application < LLoQ < LLoQ < LLoQ < LLoQ < LLoQ < LLoQ < LLoQ
Blood concentrations for (Z,Z)-10a

Time-point (h)
Concentration (ng/mL) Scaled concentration (ng/mL) Mean concentration (ng/mL) LLoQ = 1 ng/mL Scaled LLoQ = dilution factor * LLoQ = 10*1 = 10 ng/mL HLoQ= 1000 ng/mL Skin concentrations for (Z,Z)-10a LLoQ = 2 ng/mL Scaled LLoQ = dilution factor * LLoQ = 10*2 = 20 ng/mL HLoQ= 1000 ng/mL 8h-post application < LLoQ < LLoQ < LLoQ < LLoQ < LLoQ < LLoQ < LLoQ
Concentration (ng/mL) Scaled concentration (ng/mL) Mean concentration (ng/mL) LLoQ = 1 ng/mL Scaled LLoQ = dilution factor * LLoQ = 10*1 = 10 ng/mL HLoQ = 1000 ng/mL Skin concentrations for 10a LLoQ = 1 ng/mL Scaled LLoQ = dilution factor * LLoQ = 10*1 = 10 ng/mL HLoQ = 1000 ng/mL
GSH method
Test compound (10 µM) was incubated with 0.5 mg/mL human liver microsomes (Mixed Gender, Life Technologies) in 50 mM potassium phosphate buffer, pH 7.4 in the presence of either NADPH (8mg/mL) alone, glutathione alone or NADPH plus glutathione. Reactions are initiated by addition of 5 µL of 1 mM test compound (final concentration 10 µM, 1% solvent). Immediately, an aliquot (100 µL) of the incubation mixture was removed and mixed with acetonitrile (200 µL) to stop the reaction. A further 100 µL aliquot is removed at 90 minutes. After addition of 100 µL of water, the samples were centrifuged to sediment precipitated protein and the plates then sealed prior to analysis using a Xevo QTof Quadrupole Time-of-Flight Mass Spectrometer (Waters corporation, USA). Detection of metabolites is performed by analysis with MetabolynxXS and by manual data searching. Elemental composition of the parent ion and MS/MS analysis is used to determine the nature of the GSH adduct. Incubations with Clozapine were performed to provide a positive control.
Chemistry Experimental General information
Reactions using microwave irradiation were carried out in a Biotage Initiator microwave. Experimental procedures and analysis for compounds 4a-h, 9a-l and 10a-i
Sodium acetate (5.5 g, 67 mmol) was dissolved in AcOH (75 ml) and the 3-chloro-4-hydroxybenzaldehyde (5.2 g, 33.5 mmol) was added to the stirred solution. The mixture was stirred for 3 hours until a homogeneous solution was obtained. In a separate flask, the 1-isothiocyanato-2-methylbenzene (5 g, 33.5 mmol) was dissolved in DCM under nitrogen and n-propylamine (2 g, 33.5 mmol) added dropwise at room temperature (exotherm to 35 °C). The mixture was stirred for 15 minutes at room temperature then cooled in an ice-salt bath to -2 °C. The addition funnel was rinsed with DCM and bromoacetyl bromide (6.8 g, 33.5 mmol) added dropwise at such a rate as to maintain the temperature below 5 °C over 15 minutes. The mixture was stirred for 15 minutes with cooling before again rinsing the addition funnel with DCM and the dropwise addition of pyridine (5.4 g, 68.7 mmol), again keeping the temperature below 5 °C. After the addition was complete, the resulting suspension was stirred with cooling for 45 minutes then allowed to warm to room temperature. The mixture was stirred a further 60 minutes. 165.32, 154.79, 146.58, 135.83, 134.74, 132.09, 130.63, 129.84, 129.07, 129.04, 128.54, 126.83, 125.74, 120.55, 118.56, 117.27, 54.29, 23.38, 17.08, 11.68 To a solution of 2-methoxyaniline (1 g, 8 mmol) in THF (35 ml) was added triethylamine (1.2 g, 12 mmol) and the reaction cooled to -70 °C. To this was added 2-chloroacetyl chloride (0.9 g, 8 mmol) dropwise and the reaction slowly warmed to room temperature. The reaction was diluted with water, extracted with ethyl acetate and the organics dried (MgSO 4 ), filtered and concentrated to give 2-chloro-N-(2-methoxyphenyl)acetamide as a red oil (1.6 g, 98% yield).
¹H NMR (500 MHz, DMSO-d 6 ) δ: 9.48 (s, 1H), 7.98 (d, J=7.9 Hz, 1H), 7.14 -7.10 (m, 1H), 7.08 (d, J=7.0 Hz, 1H), 6.95 -6.92 (m, 1H), 4.39 (s, 2H), 3.86 (s, 3H).
To a solution of 2-chloro-N-(2-methoxyphenyl)acetamide (0.8 g, 4.0 mmol) in DMF (15 ml) was added 1-isothiocyanatopropane (405 mg, 4.0 mmol). 60% Sodium hydride (160 mg, 4.0 mmol) was added in three portions, 20 minutes apart and the reaction stirred at room temperature overnight. The reaction was quenched with water, acidified with 2 M HCl and washed with ethyl acetate. The aqueous was then basified with saturated sodium bicarbonate and extracted with ethyl acetate. The organics were dried (MgSO 4 ), filtered and concentrated to give (2Z)-3-(2-methoxyphenyl)-2-propylimino-thiazolidin-4-one as a yellow oil (350 mg, 33% yield).
¹H NMR (400 MHz, CDCl 3 ) δ: 7. 1H), 7.19 (dd, J=1.7, 7.7 Hz, 1H), 2H), 3.99 (dd, J=16.8, 27 .0 Hz, 2H), 3.82 (s, 3H), 3.31 -3.22 (m, 2H), 1.62 (s, 2H), 0.89 (dd, J=7.4, 7.4 Hz, 3H).
To a solution of (2Z)-3-(2-methoxyphenyl)-2-propylimino-thiazolidin-4-one (106 mg, 0.40 mmol) in acetic acid (1 ml) was added 3-chloro-4-hydroxy-benzaldehyde (63 mg, 0.40 mmol) and sodium acetate (66 mg, 0.80 mmol) and heated overnight at 85 °C . The reaction was cooled to room temperature, diluted with DCM and washed with water followed by sat sodium bicarbonate. The organics were collected via phase separator, concentrated and purified by column (0-100% ethyl acetate in heptane) to give (2Z,5Z)- (2Z)-3-isopropyl-2-propylimino-thiazolidin-4-one 2c
To a solution of propan-2-amine (1 g, 17 mmol) in DCM (25 ml) was added 1-isothiocyanatopropane (1.7 g, 17 mmol) and stirred at room temperature for 1.5 hours. The reaction was cooled to 0 °C on an ice bath and to this was added dropwise addition of 2-bromoacetyl bromide (3.4 g, 17 mmol). After 15 minutes pyridine (2.7 g, 34 mmol) was added and stirred at 0 °C for 20 minutes before warming to room temperature. The reaction was quenched with water, the organics collected via phase separator and concentrated. The product was purified by flash chromatography using ISCO combiflash on silica gel (40 g) eluting with ethyl acetate/heptane gradient (0-100%). Fractions corresponding to product were combined and concentrated to afford a mixture of the two regio-isomers (2Z)-3-isopropyl-2-propylimino-thiazolidin-4-one and (2Z)-2-isopropylimino-3-propyl-thiazolidin-4-one (2.8 g, 84.7% yield). 
To a solution of a mixture of (2Z)-2-isopropylimino-3-propyl-thiazolidin-4-one (200 mg, 0.99 mmol) and (2Z)-3-isopropyl-2-propylimino-thiazolidin-4-one (200 mg, 0.99 mmol) in acetic acid (5 ml) was added 3-chloro-4-hydroxy-benzaldehyde (313 mg, 1.99 mmol) and sodium acetate (328 mg, 3.99 mmol). The reaction was heated at 85 °C overnight. The reaction was cooled to room temperature, diluted with ethyl acetate and washed with water followed by sat sodium bicarbonate solution. The organics were dried, filtered and concentrated. The product was purified by flash chromatography using ISCO combiflash on silica gel (24 g) eluting with ethyl acetate/ heptane gradient (0-60%). Fractions were combined and concentrated to a yellow solid. The regioisomers were separated and purified by reverse phase preparative HPLC (Gilson acidic 60-90% gradient). Fractions were concentrated on the genevac overnight to afford (2Z,5Z)-5-[(3-chloro-4-hydroxyphenyl)methylene]-3-isopropyl-2-propylimino-thiazolidin-4-one (48 mg, 13.5% yield).
¹H NMR (400 MHz, DMSO-d 6 ) δ: 11.00 -11.00 (m, 1H), 7. 
To a solution of tetrahydropyran-4-amine (1.0 g, 9.9 mmol) in DCM (15 ml) was added 1-isothiocyanatopropane (1.0 g, 9.9 mmol) and stirred at room temperature for 1.5 hours. The reaction was cooled to 0 °C on an ice bath and 2-bromoacetyl bromide (2.0 g, 9.9 mmol) was added dropwise. After 15 minutes pyridine (1.6 g, 20 mmol) was added and stirring continued at 0 °C for 20 minutes.
The reaction was quenched with water, the organics were collected via phase separator and concentrated. The product was purified by flash chromatography using ISCO combiflash on silica gel (40 g) eluting with ethyl acetate/ heptane gradient (0-100%) to afford a mixture of regioisomers (2Z)-2-propylimino-3-tetrahydropyran-4-yl-thiazolidin-4-one and (2Z)-3-propyl-2-tetrahydropyran-4-ylimino-thiazolidin-4-one as a yellow oil (1.4 g, 59.7% yield). 
To a solution of a mixture of (2Z)-3-propyl-2-tetrahydropyran-4-ylimino-thiazolidin-4-one (200 mg, 0.99 mmol) and (2Z)-2-propylimino-3-tetrahydropyran-4-yl-thiazolidin-4-one (242 mg, 0.99 mmol) in acetic acid (5 ml) was added 3-chloro-4-hydroxy-benzaldehyde (313 mg, 1.99 mmol) and Sodium acetate (328 mg, 3.99 mmol). The reaction was heated at 85 °C overnight. The reaction was cooled to room temperature, washed with water followed by saturated sodium bicarbonate solution and the organics dried with a phase separator and concentrated. The product was purified by flash chromatography using ISCO combiflash on silica gel (40 g) eluting with ethyl acetate/ heptane gradient (0-100%). Fractions corresponding to product were combined and concentrated to a yellow solid. The regioisomers were separated and purified by reverse phase preparative HPLC (Gilson acidic 50-80% gradient) and the fractions were concentrated on the genevac overnight to afford (2Z,5Z)-5-[(3-chloro-4-hydroxy-phenyl)methylene]-2-propylimino-3-tetrahydropyran-4-yl-thiazolidin-4-one (47 mg, 11.7% yield). 
To a solution of 1,1-dioxothian-4-amine (1.0 g, 6.7 mmol) in DCM (15 ml) was added 1-isothiocyanatopropane (0.68 g, 6.7 mmol) and stirred at room temperature for 1.5 hours. The reaction was cooled to 0 °C on an ice bath and to this was added 2-bromoacetyl bromide (1.4 g, 6.7 mmol) dropwise. After 15 minutes pyridine (1.0 g, 13.4 mmol) was added and stirring continued at 0 °C for a further 20 minutes before warming to room temperature. The reaction was quenched with water. Then the organics collected via phase separator and concentrated. The product was purified by flash chromatography using ISCO combiflash on silica gel (40 g) eluting with ethyl acetate/ heptane gradient (0-100%). Fractions were combined and concentrated to afford an off-white solid with (2Z)-3-(1,1-dioxothian-4-yl)-2-propylimino-thiazolidin-4-one as the major regiosiomer in the mixture (0.46 g, 23.6% yield). 
To a solution of (2Z)-3-(1,1-dioxothian-4-yl)-2-propylimino-thiazolidin-4-one (340 mg, 1.47 mmol) and (2Z)-2-(1,1-dioxothian-4-yl)imino-3-propyl-thiazolidin-4-one (115 mg, 0.50 mmol) in acetic acid (5 ml) was added 3-chloro-4-hydroxy-benzaldehyde (463 
To a solution of 4-amino-1-methyl-piperidin-2-one dihydrochloride (1.0 g, 5.0 mmol) in DCM (25 ml) was added triethylamine (1.0 g, 10 mmol) followed by 1-isothiocyanatopropane (0.5 g, 5.0 mmol) and stirred at room temperature for 90 minutes. The reaction was cooled to 0 °C and 2-bromoacetyl bromide (1.0 g, 5.0 mmol) was added dropwise. After 15 minutes pyridine (0.8 g, 10 mmol) was added and slowly warmed to room temperature overnight. The reaction was quenched with water and the organics collected via phase separator. The organics were concentrated and purified by flash chromatography using ISCO combiflash on silica gel (24 g) eluting with ethyl acetate/ heptane gradient (0-100%) to afford a mixture of (2Z) (2Z)-3-cyclopropyl-2-propylimino-thiazolidin-4-one 2g
To a solution of cyclopropanamine (1.0 g, 18 mmol) in DCM (25 ml) was added 1-isothiocyanatopropane (1.8 g, 18 mmol) and stirred at room temperature for 1.5 hours. The reaction was cooled on an ice bath to 0 °C and to this was added 2-bromoacetyl bromide (3.5 g, 18 mmol) dropwise. After 15 minutes pyridine (2.8 g, 35 mmol) was added and stirring continued at 0 o C for 20 minutes before warming to room temperature. The reaction was quenched with water, the organics were collected via phase separator and concentrated. The product was purified by flash chromatography using ISCO combiflash on silica gel (40 g) eluting with ethyl acetate/ heptane gradient (0-100%). Fractions were combined and concentrated separately to afford (2Z)-3-cyclopropyl-2-propylimino-thiazolidin-4-one (564 mg, 14.6% Yield). (2Z,5Z)-5-[(3-chloro-4-hydroxy-phenyl)methylene]-3-cyclopropyl-2-propylimino-thiazolidin-4-one 4g
To a solution of (2Z)-3-cyclopropyl-2-propylimino-thiazolidin-4-one (200 mg, 1.00 mmol) in acetic acid (5 mL) was added 3-chloro-4-hydroxy-benzaldehyde (316 mg, 2.01 mmol) and Sodium acetate (331 mg, 4.03 mmol). The reaction was heated at 85 °C overnight. The reaction was diluted with ethyl acetate and washed with water followed by saturated sodium bicarbonate. The organics were dried via phase separator and concentrated to a yellow oil. The product was purified by flash chromatography using ISCO combiflash on silica gel (24 g) eluting with ethyl acetate/ heptane gradient (0-100%). Fractions were combined and concentrated to a yellow solid which was suspended in MeCN/ Water (1:1) formed a precipitate which was collected by vacuum filtration to afford (2Z,5Z)- 
To a solution of (2Z,5Z)-5-[(3-chloro-4-hydroxy-phenyl)methylene]-3-(2-methoxyphenyl)-2-propylimino-thiazolidin-4-one (50 mg, 0.12 mmol) in DCM (1 ml) was cooled to -70 °C under nitrogen and 1M tribromoborane (155 mg, 0.62 mmol) added dropwise. After 1 hr the reaction was quenched with 0.5 ml water and concentrated. 50% ACN/Water was added and the precipitate was collected via vacuum filtration to afford (2Z,5Z)-5-[(3-chloro-4-hydroxy-phenyl)methylene]-3-(2-hydroxyphenyl)-2-propylimino-thiazolidin-4-one (20.5 mg, 40% Yield). A solution of oxetan-3-amine (0.98 g, 13 mmol) in dry DCM (25 ml) under nitrogen had 1-isothiocyanato-2-methyl-benzene (2.0 g, 13 mmol) added over 15 minutes. Stirred at room temperature for 1 hour. Cooled to 0 °C then pyridine (2.1 g, 27 mmol) was added in a single portion.
After stirring for 5 minutes, 2-bromoacetyl bromide (2.7 g, 13 mmol) was added dropwise over 15 minutes at 0 o C. Warmed to room temperature and stirred for 2 hours. 10 ml of water was added and passed through a phase separator. Concentrated to dryness and purified by column (25-100% ethyl acetate in heptane) to give (2Z)-3-(o-tolyl)-2-(oxetan-3-ylimino)thiazolidin-4-one as an orange oil that solidified on standing for 48 hours (1.4 g, 34% yield). ( 
2Z,5Z)-5-[(3-chloro-4-hydroxy-phenyl)methylene]-3-(o-tolyl)-2-(oxetan-3-ylimino)thiazolidin-4-one 9a
DCM (12 ml) was added to (3,3-difluorocyclobutyl)ammonium chloride (1.0 g, 7.0 mmol) under nitrogen. TEA (0.9 g, 7.0 mmol) was added at room temperature, followed by addition of 1-isothiocyanato-2-methyl-benzene (1040 mg, 7.0 mmol) dropwise. Reaction was stirred at room temperature for 1 hour. Cooled in ice-bath and 2-bromoacetyl bromide (1.4 g, 7.0 mmol) added dropwise over 15 minutes. Stirred at 0 °C for 15 minutes, then pyridine (1.1 g, 14 mmol) added dropwise over 15 minutes. The resultant suspension was stirred at 0 o C for 1 hour and then warmed to room temperature for another hour. 10 ml water added and passed through phase separator. Concentrated and purified by column (0-50% ethyl acetate in heptane) to give (2Z)-2-(3,3-difluorocyclobutyl)imino-3-(o-tolyl)thiazolidin-4-one (1.5 g, 66% yield) as a yellow oil. The undesired regioisomer (2Z)-3-(3,3-difluorocyclobutyl)-2-(o-tolylimino)thiazolidin-4-one (350 mg, 18% yield) was also isolated from this column. 
thiazolidin-4-one (40 mg, 0.1 mmol) in DCM (1 ml) was cooled to -78 °C. 0.5 ml of a 1 M solution of tribromoborane (0.5 mmol) in DCM was added and stirred at -78 °C for three hours. The reaction was warmed to 0 °C and the reaction continued for 3 hours. Poured onto 50 ml ice-water and diluted with 50 ml DCM. The pH was adjusted from 1 to 7 with solid NaHCO 3 . Extracted with 2 x 50 ml DCM. Combined organics dried over sodium sulphate, filtered and concentrated and purified by column (25-100% ethyl acetate in heptane) to give (2Z,5Z)-5-[(3-chloro-4-hydroxy-phenyl)methylene]-2-(2-methoxyethylimino)-3-(o-tolyl)thiazolidin-4-one (40 mg, 35%) as a light yellow solid. A suspension of (2Z,5Z)-5-[(3-bromo-4-hydroxy-phenyl)methylene]-3-(o-tolyl)-2-propyliminothiazolidin-4-one (45 mg, 0.10 mmol), dicyanozinc (12 mg, 0.10 mmol) in DMA (0.5 ml) had nitrogen gas bubbled through for 10 minutes. Tetrakis(triphenylphosphine)palladium(0) (24 mg, 0.02 mmol) was then added and the tube sealed and heated in a microwave to 100 °C for 1.5 hours. Additional dicyanozinc (36 mg, 0.30 mmol) was added and the reaction heated at 100 °C for 12 hours. Diluted with 5 ml water. 20 ml DCM added and passed through phase separator. Solvent removed and mixture ¹H NMR (400 MHz, CDCl 3 ) δ: 7.77 (s, 1H), 7.48 (d, J=8.5 Hz, 2H), 3H), 1H), 6.86 (d, J=8.7 Hz, 2H), 6.01 (s, 1H), 2H) 165.57, 157.70, 147.08, 135.84, 134.85, 133.10, 130.60, 130.12, 129.48, 129.10, 128.96, 126.79, 125.08, 124.32, 116.44, 115.38, 54.20, 23.40, 17.09, 15.98, 11.69 1H), 7.68 (s, 1H), 7.48 (d, J=2.2 Hz, 1H), 3H), 1H), 7.26 (d, J=7.4 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 3H) 146.6, 135.8, 134.7, 132.8, 131.3, 131.1, 130.6, 129.1, 129.0, 128.7, 128.4, 126.9, 123.2, 121.1, 54.3, 23.4, 20.6, 17.1, 15.8, 11.7 Decomposition study when stored in DMSO-d 6 solution for 28 days. Hydrolysis monitored by following acetic acid CH 3 peak at 1.91 ppm. 6.3% reduction at day 28. Blue = day 1. Red = day 7. Green = day 14. Purple = day 21. Orange = day 28.
one (50 mg, 0.12 mmol) was suspended in DCM (1.5 ml) and DMAP (0.7 mg, 0.006 mmol) added, followed by dropwise addition of Et 3 N (14 mg, 0.14 mmol), whereupon a homogeneous yellow solution was obtained. The acetyl chloride (10 mg, 0.13 mmol) was added dropwise (some fuming observed). The resulting amber solution was stirred overnight. Decomposition study when stored in DMSO solution for 28 days. Hydrolysis monitored by following acetic acid CH 3 peak at 1.91 ppm. 1.4% reduction at day 28. Blue = day 1. Red = day 7. Green = day 14. Purple = day 21. Orange = day 28.
3-methoxypropanoate (53 mg, 0.12 mmol) was dissolved in CHCl3 (2 ml) under nitrogen and TMSI (99 mg, 0.50 mmol) added dropwise. The resulting yellow solution was heated at 60 °C overnight. A further 0.07 ml of TMSI was added and heating continued for a further 3 hours. The mixture was cooled and washed with water. The aqueous phase was extracted with DCM and the combined organics evaporated. Purified on silica, eluting with 100:0 to 50:50 heptane/ethyl acetate to give [2-methyl-4- Characterisation of ponesimod 146.4, 135.8, 134.7, 131.6, 130.6, 130.0, 129.1, 129.0, 128.1, 126.9, 128.8, 122.1, 119.7, 114.2, 70.5, 69.4, 62.2, 54.3, 23.4, 17.1, 11.7. HPLC tR (Agilent, acidic, 7. 
